Halia Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Study to Evaluate HT-4253 in Healthy Subjects
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Halia Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06537817
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Halia Therapeutics, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT06241742
- Locations
- 🇺🇸
CenExel JBR, Murray, Utah, United States
Study to Evaluate HT-6184 in Healthy Subjects
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Halia Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05447546
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath